Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1272421-10-9
2. Tert-butyl (3r)-3-(2-hydroxyethyl)piperazine-1-carboxylate
3. Schembl12836933
4. Xac42110
5. Mfcd18633591
6. Zinc40443128
7. Akos027251181
8. As-39240
9. (r)-1-boc-3-(2-hydroxyethyl)piperazine
10. Cs-0079238
11. (r)-t-butyl 3-(2-hydroxyethyl)piperazine-1-carboxylate
12. Tert-butyl (r)-3-(2-hydroxyethyl)piperazine-1-carboxylate
13. (r)-tert-butyl3-(2-hydroxyethyl)piperazine-1-carboxylate
| Molecular Weight | 230.30 g/mol |
|---|---|
| Molecular Formula | C11H22N2O3 |
| XLogP3 | 0.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 4 |
| Exact Mass | 230.16304257 g/mol |
| Monoisotopic Mass | 230.16304257 g/mol |
| Topological Polar Surface Area | 61.8 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 238 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Data from Phase 3 VAT08 and VAT02 efficacy study showed that two doses of Sanofi-GSK booster vaccine SP0253 or GSK4353001A (SARS-CoV-2 recombinant protein vaccine) generated an efficacy of 100%, 75%, 57.9% against severe COVID-19 disease.
Lead Product(s): SARS-CoV-2 Recombinant Protein Vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Brand Name: SP0253
Study Phase: Phase IIIProduct Type: Vaccine
Sponsor: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2022
Lead Product(s) : SARS-CoV-2 Recombinant Protein Vaccine,AS03
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : Not Applicable
Deal Type : Not Applicable
Sanofi and GSK to Seek Regulatory Authorization for Covid19 Vaccine
Details : Data from Phase 3 VAT08 and VAT02 efficacy study showed that two doses of Sanofi-GSK booster vaccine SP0253 or GSK4353001A (SARS-CoV-2 recombinant protein vaccine) generated an efficacy of 100%, 75%, 57.9% against severe COVID-19 disease.
Brand Name : SP0253
Molecule Type : Vaccine
Upfront Cash : Not Applicable
February 23, 2022
Details:
SKYCovion contains nanoparticles of recombinant Receptor Binding Domain (RBD) of SARS-CoV-2 Spike (S) protein from the parental D614G strain and an adjuvant system (AS03) and got approval by MHRA for treating COVID-19 infection.
Lead Product(s): Recombinant Adjuvanted Covid-19 Vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Brand Name: SKYCovion
Study Phase: ApprovedProduct Type: Vaccine
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023
Lead Product(s) : Recombinant Adjuvanted Covid-19 Vaccine,AS03
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Regulatory Approval of COVID-19 Vaccine SKYCovion
Details : SKYCovion contains nanoparticles of recombinant Receptor Binding Domain (RBD) of SARS-CoV-2 Spike (S) protein from the parental D614G strain and an adjuvant system (AS03) and got approval by MHRA for treating COVID-19 infection.
Brand Name : SKYCovion
Molecule Type : Vaccine
Upfront Cash : Not Applicable
May 26, 2023
Details:
Apart from Canada regulatory filing has also been initiated for USFDA and MHRA for CoVLP (Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine), the first-ever plant-based vaccine, final portion of data submitted as part of New Drug Submission COVID rolling review.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Brand Name: CoVLP
Study Phase: Phase IIIProduct Type: Vaccine
Sponsor: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2021
Lead Product(s) : Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : Not Applicable
Deal Type : Not Applicable
Medicago Submits Phase 3 Data to Health Canada for Its Plant-Based COVID-19 Vaccine Candidate
Details : Apart from Canada regulatory filing has also been initiated for USFDA and MHRA for CoVLP (Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine), the first-ever plant-based vaccine, final portion of data submitted as part of New Drug Submission CO...
Brand Name : CoVLP
Molecule Type : Vaccine
Upfront Cash : Not Applicable
December 16, 2021
Details:
Covid19 Vaccine candidate demonstrated efficacy against all variants seen in the study, including 75.3% efficacy against COVID-19 of any severity caused by the globally dominant Delta variant.
Lead Product(s): CoVLP Adjuvanted Vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Vaccine
Sponsor: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2021
Lead Product(s) : CoVLP Adjuvanted Vaccine,AS03
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Covid19 Vaccine candidate demonstrated efficacy against all variants seen in the study, including 75.3% efficacy against COVID-19 of any severity caused by the globally dominant Delta variant.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
December 07, 2021
Details:
The Phase 3 portion is an event-driven, randomized, observer-blinded, crossover placebo-controlled design that will evaluate the efficacy and safety of the CoVLP formulation, compared to placebo, in up to 30,000 subjects.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Brand Name: CoVLP
Study Phase: Phase IIIProduct Type: Vaccine
Sponsor: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2021
Lead Product(s) : Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Phase 3 portion is an event-driven, randomized, observer-blinded, crossover placebo-controlled design that will evaluate the efficacy and safety of the CoVLP formulation, compared to placebo, in up to 30,000 subjects.
Brand Name : CoVLP
Molecule Type : Vaccine
Upfront Cash : Not Applicable
May 18, 2021
Details:
Medicago’s plant-derived vaccine candidate against COVID-19 uses Coronavirus-Like-Particle (CoVLP) technology with the vaccine composed of recombinant spike (S) glycoprotein expressed as virus-like-particles (VLPs) co-administered with GSK’s pandemic adjuvant.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Brand Name: CoVLP
Study Phase: Phase IIIProduct Type: Vaccine
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
Lead Product(s) : Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Health Canada to Start Real-Time Review of Medicago COVID-19 Vaccine
Details : Medicago’s plant-derived vaccine candidate against COVID-19 uses Coronavirus-Like-Particle (CoVLP) technology with the vaccine composed of recombinant spike (S) glycoprotein expressed as virus-like-particles (VLPs) co-administered with GSK’s pandemic...
Brand Name : CoVLP
Molecule Type : Vaccine
Upfront Cash : Not Applicable
April 23, 2021
Details:
Anvisa said the companies were authorized to conduct phase 3 trials in the country. The companies are planning to test the new vaccines in around 30,000 people, in the U.S., Canada, Europe and Latin America. Brazil may have around 3,500 volunteers for the trials.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Vaccine
Sponsor: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2021
Lead Product(s) : Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : Not Applicable
Deal Type : Not Applicable
Brazilian Health Regulator Anvisa Authorizes Trials for GSK-Medicago COVID Vaccine
Details : Anvisa said the companies were authorized to conduct phase 3 trials in the country. The companies are planning to test the new vaccines in around 30,000 people, in the U.S., Canada, Europe and Latin America. Brazil may have around 3,500 volunteers for th...
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
April 08, 2021
Details:
Medicago's plant-derived vaccine candidate against COVID-19 uses Coronavirus-Like-Particle (CoVLP) technology with the vaccine composed of recombinant spike (S) glycoprotein expressed as virus-like-particles (VLPs) co-administered with GSK's pandemic adjuvant.
Lead Product(s): Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Vaccine
Sponsor: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2021
Lead Product(s) : Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine,AS03
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : National Institutes of Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Medicago and GSK Start Phase 3 Trial of Adjuvanted Covid-19 Vaccine Candidate
Details : Medicago's plant-derived vaccine candidate against COVID-19 uses Coronavirus-Like-Particle (CoVLP) technology with the vaccine composed of recombinant spike (S) glycoprotein expressed as virus-like-particles (VLPs) co-administered with GSK's pandemic adj...
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
March 16, 2021
Details:
CH8/1N1 LAIV produced a strong, functional immune response with cross-reactive antibodies targeting the hemagglutinin stalk domain, which were detectable for at least 18 months following vaccination in 65 healthy, 18 to 39-year-old US participants.
Lead Product(s): CH8/1N1 LAIV,AS03
Therapeutic Area: Infections and Infectious Diseases Brand Name: CH8/1N1 LAIV
Study Phase: Phase IProduct Type: Vaccine
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Lead Product(s) : CH8/1N1 LAIV,AS03
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Mount Sinai Researchers Advance a Universal Influenza Virus Vaccine
Details : CH8/1N1 LAIV produced a strong, functional immune response with cross-reactive antibodies targeting the hemagglutinin stalk domain, which were detectable for at least 18 months following vaccination in 65 healthy, 18 to 39-year-old US participants.
Brand Name : CH8/1N1 LAIV
Molecule Type : Vaccine
Upfront Cash : Not Applicable
December 07, 2020
Details:
Clover’s protein-based COVID-19 vaccine candidates adjuvanted with either GSK’s pandemic adjuvant system or Dynavax’s CpG 1018 plus alum induced strong neutralizing immune responses in 150 adult and elderly subjects from the Phase 1 clinical study.
Lead Product(s): Adjuvanted COVID-19 S-Trimer vaccine,AS03,CpG-1018
Therapeutic Area: Infections and Infectious Diseases Brand Name: SCB-2019
Study Phase: Phase II/ Phase IIIProduct Type: Vaccine
Sponsor: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2020
Lead Product(s) : Adjuvanted COVID-19 S-Trimer vaccine,AS03,CpG-1018
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : GSK
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Clover’s protein-based COVID-19 vaccine candidates adjuvanted with either GSK’s pandemic adjuvant system or Dynavax’s CpG 1018 plus alum induced strong neutralizing immune responses in 150 adult and elderly subjects from the Phase 1 clinical study.
Brand Name : SCB-2019
Molecule Type : Vaccine
Upfront Cash : Not Applicable
December 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
